Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100004090
Beijing Wantai Biological Pharmacy Enterprise Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.25 bn CNY | 1.82 bn CNY |
| Gross profit | 1.38 bn CNY | 897.14 m CNY |
| Operating income | 93.84 m CNY | -426.41 m CNY |
| EBIT | -315.37 m CNY | -474.43 m CNY |
| Net income | 106.24 m CNY | -398.27 m CNY |
| Diluted EPS – continuing operations | 0.08 CNY | -0.31 CNY |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections; P-85 Ab for nasopharyngeal cancer screening; and TB-IGRA for large population screening. It also provides diagnostic assays, such as high-value Hepatitis B core antibody tests, Hepatitis E Urine tests, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays; and enzyme-linked immunosorbent assay (ELISA), colloidal gold, molecular, clinical laboratory quality control products, and bioactive materials for various infectious diseases, such as HIV, Hepatitis, Tuberculosis, and Influenza A/B. In addition, the company offers core diagnostic solutions comprising chronic disease management, integrated Hepatitis E screening and prevention, full lifecycle women's health programs, and intelligent laboratory services. Further, it provides medical instruments, diagnostic tests, quality control products, bioactive materials, and diagnostics solutions; and HPV, Hepatitis E, and Nasal Spray COVID-19 vaccines. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.
More stocks
- Sabra Health Care REIT, Inc. (SBRA)
- Sanwa Holdings Corp (5929.T)
- Benefit Systems SA (BFT.WA)
- Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329.SS)
- GRANITE CONSTRUCTION INC (GVA)
- E-L Financial Corp Ltd (ELF.TO)
- Phillips Edison & Company, Inc. (PECO)
- DiaSorin SpA (DIA.MI)
- Sweco AB (publ) (SWEC B.ST)
- Groupe Dynamite Inc (GRGD.TO)
- Formosa Sumco Technology Corp (3532.TW)
- Rithm Capital Corp. (RITM)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.